Literature DB >> 20237554

Multiple sclerosis: closing in on an oral treatment.

Roland Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20237554     DOI： 10.1038/464360a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  17 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

3.  FTY720 modulates human oligodendrocyte progenitor process extension and survival.

Authors:  Veronique E Miron; Cha Gyun Jung; Hye Jung Kim; Timothy E Kennedy; Betty Soliven; Jack P Antel
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

4.  FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

Authors:  D D Pinschewer; A F Ochsenbein; B Odermatt; V Brinkmann; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

5.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

Authors:  K Chiba; Y Yanagawa; Y Masubuchi; H Kataoka; T Kawaguchi; M Ohtsuki; Y Hoshino
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.

Authors:  F Leypoldt; A Münchau; F Moeller; M Bester; C Gerloff; C Heesen
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

8.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

Authors:  Ana M Pascual; Neus Téllez; Isabel Boscá; Javier Mallada; Antonio Belenguer; Inmaculada Abellán; Angel P Sempere; Pascual Fernández; Ma José Magraner; Francisco Coret; Miguel A Sanz; Xavier Montalbán; Bonaventura Casanova
Journal:  Mult Scler       Date:  2009-10-13       Impact factor: 6.312

10.  Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone.

Authors:  Guy Cinamon; Mehrdad Matloubian; Matthew J Lesneski; Ying Xu; Caroline Low; Theresa Lu; Richard L Proia; Jason G Cyster
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606
View more
  5 in total

1.  FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.

Authors:  Ji Woong Choi; Shannon E Gardell; Deron R Herr; Richard Rivera; Chang-Wook Lee; Kyoko Noguchi; Siew Teng Teo; Yun C Yung; Melissa Lu; Grace Kennedy; Jerold Chun
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-21       Impact factor: 11.205

Review 2.  Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis.

Authors:  Peng-fei Hu; Yi Chen; Peng-fei Cai; Li-feng Jiang; Li-dong Wu
Journal:  Mol Biol Rep       Date:  2010-11-30       Impact factor: 2.316

3.  Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

Authors:  Hany A Omar; Chih-Chien Chou; Lisa D Berman-Booty; Yihui Ma; Jui-Hsiang Hung; Dasheng Wang; Takayuki Kogure; Tushar Patel; Luigi Terracciano; Natarajan Muthusamy; John C Byrd; Samuel K Kulp; Ching-Shih Chen
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.298

4.  Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Authors:  Amanda M Smith; Matthew D Dun; Erwin M Lee; Celeste Harrison; Richard Kahl; Hayley Flanagan; Nikita Panicker; Baratali Mashkani; Anthony S Don; Jonathan Morris; Hamish Toop; Richard B Lock; Jason A Powell; Daniel Thomas; Mark A Guthridge; Andrew Moore; Leonie K Ashman; Kathryn A Skelding; Anoop Enjeti; Nicole M Verrills
Journal:  Oncotarget       Date:  2016-07-26

Review 5.  More than Just an Immunosuppressant: The Emerging Role of FTY720 as a Novel Inducer of ROS and Apoptosis.

Authors:  Teruaki Takasaki; Kanako Hagihara; Ryosuke Satoh; Reiko Sugiura
Journal:  Oxid Med Cell Longev       Date:  2018-03-28       Impact factor: 6.543
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.